Sotac Pharmaceuticals Past Earnings Performance
Past criteria checks 5/6
Sotac Pharmaceuticals has been growing earnings at an average annual rate of 41.7%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 18.1% per year. Sotac Pharmaceuticals's return on equity is 8.2%, and it has net margins of 4.2%.
Key information
41.7%
Earnings growth rate
37.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 18.1% |
| Return on equity | 8.2% |
| Net Margin | 4.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Here's Why We Think Sotac Pharmaceuticals (NSE:SOTAC) Is Well Worth Watching
Sep 28
We Think Sotac Pharmaceuticals (NSE:SOTAC) Is Taking Some Risk With Its Debt
Jul 24Sotac Pharmaceuticals Limited's (NSE:SOTAC) 31% Price Boost Is Out Of Tune With Earnings
Jun 28Sotac Pharmaceuticals Limited (NSE:SOTAC) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Feb 29Revenue & Expenses Breakdown
How Sotac Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,056 | 45 | 36 | 0 |
| 30 Jun 24 | 1,041 | 46 | 40 | 0 |
| 31 Mar 24 | 1,040 | 43 | 40 | 0 |
| 31 Dec 23 | 955 | 31 | 40 | 0 |
| 30 Sep 23 | 894 | 25 | 43 | 0 |
| 30 Jun 23 | 826 | 27 | 44 | 0 |
| 31 Mar 23 | 775 | 29 | 43 | 0 |
| 31 Mar 22 | 732 | 29 | 30 | 0 |
| 31 Mar 21 | 488 | -24 | 32 | 0 |
| 31 Mar 20 | 286 | 1 | 17 | 0 |
Quality Earnings: SOTAC has high quality earnings.
Growing Profit Margin: SOTAC's current net profit margins (4.2%) are higher than last year (2.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SOTAC's earnings have grown significantly by 41.7% per year over the past 5 years.
Accelerating Growth: SOTAC's earnings growth over the past year (81.2%) exceeds its 5-year average (41.7% per year).
Earnings vs Industry: SOTAC earnings growth over the past year (81.2%) exceeded the Pharmaceuticals industry 19.1%.
Return on Equity
High ROE: SOTAC's Return on Equity (8.2%) is considered low.